News

Ebola Pandemic Risk in 2026: A Low Probability Assessment

An Ebola pandemic in 2026 is considered unlikely due to established public health responses, vaccine availability, and improved surveillance.

ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements

ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.

Tirzepatide: Efficacy in Weight Management Explored at ATS 2026

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.

BRINSUPRI® First Therapy Approved for NCFB at ATS 2026

BRINSUPRI® receives first approval for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet need in chronic respiratory care.

YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients

YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma

Alpha-1 antitrypsin (AAT) protein extends its protective role beyond established AAT deficiency, influencing general lung health.

Epithelial Dysfunction: A Unified Target in Airway Disease Management

ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.

Triple Therapy Optimises COPD Outcomes at ATS 2026

ATS 2026 presentations highlight tailored triple therapy for obstructive lung disease, improving lung function and reducing exacerbations.

JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD

Nerandomilast, a novel anti-inflammatory agent, demonstrates efficacy in reducing exacerbation rates in patients with moderate to severe COPD.

ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease

ATS 2026 highlights the persistent gap in objective cough assessment in respiratory diseases, hindering precise diagnosis and treatment efficacy.